» Articles » PMID: 22745357

Disease Profile and Differential Diagnosis of Hereditary Transthyretin-related Amyloidosis with Exclusively Cardiac Phenotype: an Italian Perspective

Abstract

Aims: Hereditary transthyretin (TTR)-related amyloidosis (ATTR) is mainly considered a neurologic disease. We assessed the phenotypic and genotypic spectra of ATTR in a Caucasian area and evaluated the prevalence, genetic background, and disease profile of cases with an exclusively cardiac phenotype, highlighting possible hints for the differential diagnosis with hypertrophic cardiomyopathy (HCM) and senile systemic amyloidosis (SSA).

Methods And Results: In this Italian multicentre study, 186 patients with ATTR were characterized at presentation. Thirty patients with SSA and 30 age-gender-matched HCM patients were used for comparison. Phenotype was classified as exclusively cardiac (n = 31, 17%), exclusively neurologic (n = 46, 25%), and mixed cardiac/neurologic (n = 109, 58%). Among the eight different mutations responsible for an exclusively cardiac phenotype, Ile68Leu was the most frequent. Five patients with an exclusively cardiac phenotype developed mild abnormalities at neurological examination, but no symptoms during a 36-month follow-up (range: 14-50). Exclusively cardiac phenotype was characterized by male gender, age >65 years, heart failure symptoms, symmetric left ventricular (LV) 'hypertrophy', and moderately depressed LV ejection fraction. This profile was similar to SSA, but relatively distinct from HCM. Compared with patients with a mixed phenotype, patients with an exclusively cardiac phenotype showed a more pronounced cardiac involvement on both echocardiogram and electrocardiogram (ECG).

Conclusion: A clinically relevant subset of Caucasian ATTR patients present with an exclusively cardiac phenotype, mimicking HCM or SSA. Echocardiographic and ECG findings are useful to differentiate ATTR from HCM but not from SSA. The role of liver transplantation in these patients should be reconsidered.

Citing Articles

Echocardiographic red flags in transthyretin amyloid cardiomyopathy: all that glitters is not gold.

De Michieli L, Sinigiani G, Nistri S, Cipriani A Eur Heart J Imaging Methods Pract. 2024; 2(3):qyae114.

PMID: 39679325 PMC: 11645158. DOI: 10.1093/ehjimp/qyae114.


Hereditary vitreoretinal amyloidosis with transthyretin Gly83Arg variant, a long-term study.

Chen X, Xin C, Su G, Xie B, Li H, Ren H Eye (Lond). 2024; 39(2):345-353.

PMID: 39478196 PMC: 11750974. DOI: 10.1038/s41433-024-03445-y.


Diagnosing AL and ATTR Amyloid Cardiomyopathy: A Multidisciplinary Approach.

Aus dem Siepen F, Hansen T J Clin Med. 2024; 13(19).

PMID: 39407933 PMC: 11477302. DOI: 10.3390/jcm13195873.


Electrocardiographic Patterns and Arrhythmias in Cardiac Amyloidosis: From Diagnosis to Therapeutic Management-A Narrative Review.

Teresi L, Trimarchi G, Liotta P, Restelli D, Licordari R, Carciotto G J Clin Med. 2024; 13(18).

PMID: 39337075 PMC: 11432666. DOI: 10.3390/jcm13185588.


Epidemiological Changes in Transthyretin Cardiac Amyloidosis: Evidence from In Vivo Data and Autoptic Series.

Cianci V, Cianci A, Sapienza D, Craco A, Germana A, Ieni A J Clin Med. 2024; 13(17).

PMID: 39274353 PMC: 11396392. DOI: 10.3390/jcm13175140.